Perfusion cultures of human tumor cells: A scalable production platform for oncolytic adenoviral vectors

Biotechnology and Bioengineering

Volumn 86, Issue 6, 2004, Pages 637-642

  Yuk, Inn H Y ^a,b   Olsen, Matthew M ^a   Geyer, Scott ^a   Forestell, Sean P ^a  

^a ONYX PHARMACEUTICALS   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Adenovirus production; High density cell culture; Human tumor cells; Oncolytic adenoviral vectors; Perfusion bioreactors

Indexed keywords

BIOREACTORS; CELLS; ONCOLOGY; TUMORS; VIRUSES;

ADENOVIRAL VECTORS; VECTOR RECOMBINANTS;

TISSUE CULTURE;

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS;

ARTICLE; BIOREACTOR; BIOTECHNOLOGY; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; BIOREACTORS; BIOTECHNOLOGY; CELL COUNT; CELL SURVIVAL; FEASIBILITY STUDIES; GENETIC VECTORS; HELA CELLS; HUMANS; PERFUSION;

ADENOVIRIDAE;

EID: 2542447236     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20158     Document Type: Article

References (20)

1. Biblia TA, Robinson DK. 1995. In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol Progr 11:1-13.
2. Forestell S, Celeri C, Dang C, Gong T, Olsen M, Sifi I, Yuk I, Geyer S. 2003. Comparison of host cell lines and production methods for a new generation of oncolytic adenoviral vectors. In: Godia F, editor. Animal cell technology meets genomics. Dordrecht: Kluwer.
3. Furey J. 2002. Scale-up of a cell culture perfusion process. Gen Eng News 22:62-63.
4. Gey GO, Coffman WD, Kubicek MT. 1952. Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 12:264-265.
5. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
6. Hehir KM, Armentano D, Cardoza LM, Choquette TL, Berthelette PB, White GA, Couture LA, Everton MB, Keegan J, Martin JM, Pratt DA, Smith MP, Smith AE, Wadsworth SC. 1996. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J Virol 70: 8459-8467.
7. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. 2002. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1:325-337.
8. Kirn D, Martuza RL, Zwiebel J. 2001. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7:781-787.
9. Lee YY, Yap MGS, Hu WS, Wong KTK. 2003. Low-glutamine fed-batch cultures of 293-HEK serum-free suspension cells for adenovirus production. Biotechnol Progr 19:501-509.
10. Mercille S, Massie B. 1999. Apoptosis-resistant E1B-19K-expressing NS/0 myeloma cells exhibit increased viability and chimeric antibody productivity under perfusion culture conditions. Biotechnol Bioeng 63:529-543.
11. Nadeau I, Garnier A, Cote J, Massie B, Chavarie C, Kamen A. 1996. Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotechnol Bioeng 51:613-623.
12. Nadeau I, Kamen A. 2003. Production of adenovirus vector for gene therapy. Biotechnol Adv 20:475-489.
13. Puck TT, Marcus PI, Cieciura SJ. 1956. Clonal growth of mammalian cells in vitro. J Exp Med 103:273-283.
14. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ, Sutjipto S. 1997. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8:453-465.
15. Siegwart P, Cote J, Male K, Luong JHT, Perrier M, Kamen A. 1999. Adaptive control at low glucose concentration of HEK-293 serum-free cultures. Biotechnol Progr 15:608-616.
16. Sluzky V, Xue S, Schulz C, Schmidt B, Uyechi-O'Brien L. 2002. Analytical challenges for characterization and stability testing of a selectively replicating adenovirus in late stages of clinical development. Presented at Viral Vectors and Vaccines Conference, ninth annual meeting. New Orleans, Louisiana, 2002.
17. Voisard V, Meuwly F, Ruffieux PA, Baer G, Kadouri A. 2003. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol Bioeng 82:751-765.
18. Woodside SM, Bowen BD, Piret JM. 1998. Mammalian cell retention devices for stirred perfusion bioreactors. Cytotechnology 28:163-175.
19. Xie L, Metallo C, Warren J, Pilbrough W, Peltier J, Zhong T, Pikus L, Yancy A, Leung J, Aunins JG, Zhou W. 2003. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 cell culture under sparging conditions. Biotechnol Bioeng 83:45-52.
20. Zhu J, Grace M, Casale J, Chang AT-I, Musco ML, Bordens R, Greenberg R, Schaefer E, Indelicato SR. 1999. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum Gene Ther 10:113-121.